Source: http://www.google.com/patents/US8148342?dq=3798360
Timestamp: 2016-05-24 10:04:39
Document Index: 279785718

Matched Legal Cases: ['Application No. 200580032715', 'Application No. 00914455', 'Application No. 00914455', 'Application No. 00914455', 'Application No. 00914455', 'Application No. 00914455', 'Application No. 00914455', 'Application No. 2007', 'Application No. 553987', 'Application No. 200580032715', 'Application No. 200702035', 'Application No. 200702035', 'Application No. 2007', 'Application No. 2007', 'Application No. 2007', 'Application No. 00914455', 'Application No. 200702035']

Patent US8148342 - Oligoribonucleotides and methods of use thereof for treatment of alopecia ... - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsThe invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of a human p53 gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and...http://www.google.com/patents/US8148342?utm_source=gb-gplus-sharePatent US8148342 - Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseasesAdvanced Patent SearchPublication numberUS8148342 B2Publication typeGrantApplication numberUS 12/008,578Publication dateApr 3, 2012Filing dateJan 11, 2008Priority dateSep 28, 2004Fee statusPaidAlso published asCA2580126A1, CA2580126C, CN102643818A, CN102643818B, EP1799269A2, EP1799269A4, US7842674, US8765699, US9006196, US9334499, US20060069056, US20080287382, US20090082291, US20120184597, US20150141487, WO2006035434A2, WO2006035434A3Publication number008578, 12008578, US 8148342 B2, US 8148342B2, US-B2-8148342, US8148342 B2, US8148342B2InventorsElena Feinstein, Shai EhrlichOriginal AssigneeQuark Pharmaceuticals Inc.Export CitationBiBTeX, EndNote, RefManPatent Citations (66), Non-Patent Citations (108), Referenced by (6), Classifications (9), Legal Events (1) External Links: USPTO, USPTO Assignment, EspacenetOligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4497817Apr 26, 1983Feb 5, 1985Yamanouchi Pharmaceutical Co., Ltd.2-Phenylimidazo [2,1-b]benzothiazole derivativesUS5849774 *Jul 3, 1996Dec 15, 1998University Of PittsburghTreatment of sepsis-induced acute renal failureUS5898031Jun 6, 1996Apr 27, 1999Isis Pharmaceuticals, Inc.Oligoribonucleotides for cleaving RNAUS6107094Jun 6, 1997Aug 22, 2000Isis Pharmaceuticals, Inc.Oligoribonucleotides and ribonucleases for cleaving RNAUS6372249Oct 24, 1994Apr 16, 2002Baylor College Of MedicineSenscent cell-derived inhibitors of DNA synthesisUS6506559Dec 18, 1998Jan 14, 2003Carnegie Institute Of WashingtonGenetic inhibition by double-stranded RNAUS6593353Jan 28, 2000Jul 15, 2003Board Of Trustees Of The University Of Illinoisp53 inhibitors and therapeutic use of the sameUS6982277Jan 24, 2003Jan 3, 2006The Board Of Trutees Of The University Of IllinoisP53 inhibitors and therapeutic use of the sameUS7008956Jan 28, 2003Mar 7, 2006The Board Of Trustees Of The University Of Illinoisp53 inhibitors and therapeutic use of the sameUS7012087Jun 13, 2001Mar 14, 2006The Board Of Trustees Of The University Of Illinoisp53 inhibitors and therapeutic use of the sameUS7056704Apr 27, 2004Jun 6, 2006Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V.RNA interference mediating small RNA moleculesUS7078196Apr 27, 2004Jul 18, 2006Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften, E.V.RNA interference mediating small RNA moleculesUS7432249Oct 25, 2002Oct 7, 2008Isis Pharmaceuticals, Inc.Oligoribonucleotides and ribonucleases for cleaving RNAUS7432250Oct 25, 2002Oct 7, 2008Isis Pharmaceuticals, Inc.Oligoribonucleotides and ribonucleases for cleaving RNAUS7452987Aug 5, 2003Nov 18, 2008Silence Therapeutics Aktiengesellschaft (Ag)Interfering RNA moleculesUS7459547Jun 2, 2004Dec 2, 2008University Of MassachusettsMethods and compositions for controlling efficacy of RNA silencingUS7629321Dec 8, 2009Isis Pharmaceuticals, Inc.Oligoribonucleotides and ribonucleases for cleaving RNAUS7741299Jun 22, 2010Quark Pharmaceuticals, Inc.Therapeutic uses of inhibitors of RTP801US7781575Sep 18, 2009Aug 24, 2010Dharmacon, Inc.siRNA targeting tumor protein 53 (p53)US7825099Jan 18, 2007Nov 2, 2010Quark Pharmaceuticals, Inc.Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genesUS7842674Nov 30, 2010Quark Pharmaceuticals Inc.Methods of treatment of acute renal failureUS7893245Feb 22, 2011Silence Therapeutics Aktiengesellschaft (Ag)Interfering RNA moleculesUS7910566Mar 22, 2011Quark Pharmaceuticals Inc.Prevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNAUS20020019425Sep 6, 2001Feb 14, 2002The Board Of Trustees Of The University Of Illinoisp53 Inhibitors and therapeutic use of the sameUS20040014956Feb 3, 2003Jan 22, 2004Sequitur, Inc.Double-stranded oligonucleotidesUS20040180351Aug 5, 2003Sep 16, 2004Atugen AgInterfering RNA moleculesUS20040209832Sep 23, 2003Oct 21, 2004Mcswiggen JamesRNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)US20050080246Jun 3, 2004Apr 14, 2005Charles AllersonCompositions comprising alternating 2'-modified nucleosides for use in gene modulationUS20050255487Sep 14, 2004Nov 17, 2005Dharmacon, Inc.Methods and compositions for selecting siRNA of improved functionalityUS20050261191 *May 6, 2005Nov 24, 2005Barasch Jonathan MNGAL for reduction and amelioration of ischemic and nephrotoxic injuriesUS20060069056Sep 27, 2005Mar 30, 2006Elena FeinsteinOligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseasesUS20060217329Aug 16, 2005Sep 28, 2006Elena FeinsteinTherapeutic uses of inhibitors of RTP801US20070031844Nov 14, 2003Feb 8, 2007Anastasia KhvorovaFunctional and hyperfunctional siRNAUS20070185047Dec 1, 2006Aug 9, 2007Balkrishen BhatDouble strand compositions comprising differentially modified strands for use in gene modulationUS20080108583Jan 18, 2007May 8, 2008Elena FeinsteinTreatment or prevention of oto-pathologies by inhibition of pro-apoptotic genesUS20080161426Jan 30, 2008Jul 3, 2008The Board Of Trustees Of The University Of Illinoisp53 Inhibitors and Therapeutic Use of the SameUS20080287382Jan 11, 2008Nov 20, 2008Quark Pharmaceuticals, Inc.Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseasesUS20090082291Jul 10, 2007Mar 26, 2009Quark Biotech, Inc.Methods of treatment of acute renal failureUS20090105173Jan 4, 2008Apr 23, 2009Elena FeinsteinPrevention and treatment of acute renal failure and other kidney diseases by inhibition of p53 by siRNAUS20100029746Feb 4, 2010Quark Pharmaceuticals, Inc.Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genesUS20100048425Feb 25, 2010Dharmacon, Inc.siRNA targeting tumor protein 53 (P53)EP0430334A1Nov 15, 1990Jun 5, 1991Janssen Pharmaceutica N.V.Immunostimulating 6-aryl-5,6-dihydroimidazo[2,1-b]thiazole derivativesEP2284266A2Nov 14, 2003Feb 16, 2011Dharmacon, Inc.Functional and hyperfunctional sirnaWO1999055910A1Feb 22, 1999Nov 4, 1999Arizona Board Of RegentsMethod of inducing apoptosis in a target cellWO2000044895A1Jan 29, 2000Aug 3, 2000Roland KreutzerMethod and medicament for inhibiting the expression of a defined geneWO2000044914A1Jan 28, 2000Aug 3, 2000Medical College Of Georgia Research Institute, Inc.Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rnaWO2001036646A1Nov 17, 2000May 25, 2001Cancer Research Ventures LimitedInhibiting gene expression with dsrnaWO2001068836A2Mar 16, 2001Sep 20, 2001Genetica, Inc.Methods and compositions for rna interferenceWO2001075164A2Mar 30, 2001Oct 11, 2001Whitehead Institute For Biomedical ResearchRna sequence-specific mediators of rna interferenceWO2002044321A2Nov 29, 2001Jun 6, 2002MAX-PLANCK-Gesellschaft zur F�rderung der Wissenschaften e.V.Rna interference mediating small rna moleculesWO2002055693A2Jan 9, 2002Jul 18, 2002Ribopharma AgMethod for inhibiting the expression of a target geneWO2002059300A2Dec 28, 2001Aug 1, 2002J & J Research Pty LtdDouble-stranded rna-mediated gene suppressionWO2003062394A2Jan 22, 2003Jul 31, 2003Cold Spring Harbor LaboratoryMethods and compositions for rna interferenceWO2003064625A2Feb 3, 2003Aug 7, 2003Sequitur, Inc.Oligonucleotide compositions with enhanced efficiencyWO2003064626A2Feb 3, 2003Aug 7, 2003Sequitur, Inc.Double-stranded oligonucleotidesWO2003070918A2Feb 20, 2003Aug 28, 2003Ribozyme Pharmaceuticals, IncorporatedRna interference by modified short interfering nucleic acidWO2003074654A2Feb 20, 2003Sep 12, 2003Sirna Therapeurics, IncRna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)WO2004015107A2Aug 5, 2003Feb 19, 2004Atugen AgFurther novel forms of interfering rna moleculesWO2004041889A2Nov 4, 2003May 21, 2004Isis Pharmaceuticals, Inc.Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulationWO2004044136A2Nov 4, 2003May 27, 2004Isis Pharmaceuticals, Inc.Compositions comprising alternating 2’-modified nucleosides for use in gene modulationWO2004111191A2Jun 2, 2004Dec 23, 2004University Of MassachusettsMethods and compositions for controlling efficacy of rna silencingWO2005062937A2Dec 22, 2004Jul 14, 2005University Of MassachusettsMethods and compositions for enhancing the efficacy and specificity of single and double blunt-ended sirnaWO2006006948A2May 12, 2004Jan 19, 2006Dharmacon, Inc.METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITYWO2006035434A2Sep 27, 2005Apr 6, 2006Quark Biotech, Inc.Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseasesWO2007087451A2Jan 25, 2007Aug 2, 2007University Of MassachusettsCompositions and methods for enhancing discriminatory rna interferenceWO2009001359A2Jun 26, 2008Dec 31, 2008Quark Pharmaceuticals, Inc.Compositions and methods for inhibiting expression of pro-apoptotic genes* Cited by examinerNon-Patent CitationsReference189. Pending claims in U.S. Appl. No. 11/136,231, filed May 24, 2005.2Amarzguioui M et al. (2003) Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 31(2):589-95.3Andrei Gudkov et al., U.S. Appl. No. 11/136,231, filed May 24, 2005.4Aug. 12, 2010 Response and Amendment to First Office Action issued Mar. 29, 2010 in connection with Chinese Patent Application No. 200580032715.4 filed Sep. 27, 2005.5Barik, Sailen (2005.). "Silence of the Transcripts; RNA Interference in Medicine," J. Mol. Med. 83:764-773.6Bartel, D.P., (2004) MicroRNAs: Genomics, Biogenesis, Mechanism, and Function. Cell 116:281-297.7Bernstein, E., et al., (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409:363-366.8Bitko, Vira et al. (2004). "Inhibition of Respiratory Viruses by Nasally Administered siRNA," Nature Medicine, 11(1):50-55.9Botchkarev, V.A., et al., (2000) p53 Is Essential for Chemotherapy-induced Hair Loss. Cancer Res. 60:5002-5006.10Brummelkamp, T.R., et al., (2002) A System for Stable Expression of Short Interfering RNAs in Mammalian Cells. Science 296:550-553.11Caplen, N.J., et al., (2001) Specific inhibition of gene expression by small-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA 98(17):9742-9747.12Chakraborty, Chiranjib (2007) "Potentially of Small Interfering RNAs (siRNA) as Recent Therapeutic Targets for Gene-Silencing," Current Drug Targets, 8:469-482.13Chalk, A.M., et al., (2004) Improved and automated prediction of effective siRNA. Biochem. Biophys. Res. Commun. 319:264-274.14Chernov, M.V. and Stark, G.R., (1997) The p53 activation and apoptosis induced by DNA damage are reversibly inhibited by salicylate. Oncogene 14:2503-2510.15Chiu et al., siRNA Function in RNAi: A Chemical modification analysis, RNA, (2003), 9:1034-1048.16Communication pursuant to Article 96(2)EPC issued by the European Patent Office on Aug. 19, 2004 in connection with European Patent Application No. 00914455.1.17Communication pursuant to Article 96(2)EPC issued by the European Patent Office on Feb. 12, 2004 in connection with European Patent Application No. 00914455.1.18Communication pursuant to Article 96(2)EPC issued by the European Patent Office on March 10, 2006 in connection with European Patent Application No. 00914455.1.19Communication pursuant to Article 96(2)EPC issued by the European Patent Office on May 13, 2005 in connection with European Patent Application No. 00914455.1.20Communication pursuant to Article 96(2)EPC issued by the European Patent Office on Oct. 24, 2006 in connection with European Patent Application No. 00914455.1.21Communication under Rule 112 EPC issued by the European Patent Office on Dec. 16, 2003 in connection with European Patent Application No. 00914455.1.22Cotsarelis, G. and Millar, S.E., (2001) Towards a molecular understanding of hair loss and its treatment. Trends Mol. Med. 7(7):293-301.23Czauderna F, et al. (2003) Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31(11):2705-16.24Decision of Grant issued by the Russian Patent Office on Apr. 4, 2011 in connection with Russian Patent Application No. 2007/116168.25Elbashir SM et al. (2001) Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 20(23):6877-88.26Elbashir, S.M., et al., (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494-498.27Elbashir, S.M., et al., (2001) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev. 15:188-200.28Elena Feinstein, et al., U.S. Appl. No. 11/827,199, filed Jul. 10, 2007.29Examination Report issued by the Australian Patent Office on Dec. 22, 2008 in connection with New Zealand Patent Application No. 553987.30Final Office Action issued Dec. 3, 2007 in connection with U.S. Appl. No. 11/237,598, filed Sep. 27, 2005.31Final Office Action issued on Aug. 19, 2009 in connection with U.S. Appl. No. 11/237,598, filed Sep. 27, 2005.32Fire, A., et al., (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806-811.33First Office Action issued Mar. 29, 2010 in connection with Chinese Patent Application No. 200580032715.4 filed Sep. 27, 2005.34Gottlieb, T.M., et al., (1996) p53 in growth control and neoplasia. Biochim Biophys Acta 1287:77-102.35Hall et al., RNA interference using boranophosphate siRNAs: structure-activity relationships, nucleic acids research, (2004), vol. 32(20): 5991-6000.36International Preliminary Report on Patentability issued by WIPO on Apr. 2, 2009 in connection with International Application No. PCT/IL2005/001035.37International Search Report issued by the International Searching Authority (ISA/US) on Dec. 3, 2007 in connection with International Application No. PCT/IL05/01035.38Jan. 27, 2010 Exam Report and decision of grant in connection with Singapore Application No. 200702035-7.39 *Kelly et al. Journal of the American Society of Nephrology 2003 vol. 14, pp. 128-138.40Komarov, P.G., et al., (1999) A Chemical Inhibitor of p53 That Protects Mice from the Side Effects of Cancer Therapy. Science 285:1733-1737.41Komarova, E.A., et al., (1997) Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal . . . EMBO J. 16(6):1391-1400.42Layzer et al., In vivo activity if nuclease-resistant siRNAs, RNA, (2004), 10: 766-771.43Lee, Youngtae et al., (2003). "The nuclear RNase III Drosha initiates mircoRNA processing," Nature, 425:415-419.44Levenkova, N., et al., (2004) Gene specific siRNA selector. Bioinformatics 20(3):430-432.45 *Matta et al. Cancer Biology & Therapy 2003, vol. 2, pp. 206-210.46McManus, M.T. and Sharp, P.A., (2002) Gene Silencing in Mammals by Small Interfering RNAs. Nature Rev. Genet. 3:737-747.47Molitoris, BA (2003) "Transitioning to Therapy in Ischemic Acute Renal Failure." J. Am. Soc. Nephrol. 14: 265-267.48Molitoris, BA et al. (2009) "siRNA Targeted to p53 Attenuates Ischemic and Cisplatin-Induced Acute Kidney Injury", JASN Express, 20: 1754-1764.49Non-Final Office Action Summary for U.S. Appl. No. 11/655,610 (Responsive to communication filed on Jan. 18, 2007).50Non-Final Office Action Summary for U.S. Appl. No. 11/655,610 (Responsive to communication filed on Jul. 3, 2008).51Notice of Allowance and Allowed Claims in U.S. Appl. No. 12/586,271 (US 2010/0048425), 2010.52Notice of Allowance mailed on Apr. 7, 2009 in connection with Elena Feinstein et al., U.S. Appl. No. 11/655,610, filed Jan. 18, 2007.53Notice of Allowance mailed on Jul. 22, 2010 in connection with Elena Feinstein et al., U.S. Appl. No. 11/827,199, filed Jul. 10, 2007.54Notice of Allowance mailed on Nov. 18, 2009 in connection with U.S. Appl. No. 11/237,598, filed Sep. 27, 2005, and allowed claims.55Notice of Allowance mailed on Nov. 5, 2010 in connection with Elena Feinstein et al., U.S. Appl. No. 12/006,722, filed Jan. 4, 2008.56Nov. 10, 2010 Amendment and Response to Office Action issued May 10, 2010 in connection with U.S. Appl. No. 11/237,598, filed Sep. 27, 2005.57Oct. 26, 2009 Response to Second Written Opinion issued by the Australian Patent Office on May 26, 2009 in connection with Singapore Application No. 200702035-7.58Office Action issued by the Japanese Patent Office on Feb. 8, 2011 in connection with Japanese Patent Application No. 2007-534174.59Office Action issued by the Russian Patent Office on Jul. 20, 2009 in connection with Russian Patent Application No. 2007/116168.60Office Action issued by the Russian Patent Office on Jun. 2, 2010 in connection with Russian Patent Application No. 2007/116168.61Office Action issued Feb. 15, 2011 in connection with U.S. Appl. No. 11/237,598, filed Sep. 27, 2005.62Office Action issued Mar. 14, 2007 in connection with U.S. Appl. No. 11/237,598, filed Sep. 27, 2005.63Office Action issued May 10, 2010 in connection with U.S. Appl. No. 11/237,598, filed Sep. 27, 2005.64Office Action issued Nov. 9, 2006 in connection with U.S. Appl. No. 11/237,598, filed Sep. 27, 2005.65Office Action issued on Apr. 21, 2005 in connection with U.S. Appl. No. 10/352,597, filed Jan. 28, 2003.66Office Action issued on Apr. 6, 2004 in connection with U.S. Appl. No. 10/350,560, filed Jan. 24, 2003.67Office Action issued on Dec. 28, 2001 in connection with U.S. Appl. No. 09/947,757, filed Sep. 6, 2001.68Office Action issued on Feb. 12, 2003 in connection with U.S. Appl. No. 09/880,417, filed Jun. 13, 2001.69Office Action issued on Jan. 3, 2005 in connection with U.S. Appl. No. 10/350,560, filed Jan. 24, 2003.70Office Action issued on Jul. 13, 2004 in connection with U.S. Appl. No. 09/947,757, filed Sep. 6, 2001.71Office Action issued on Jul. 15, 2001 in connection with U.S. Appl. No. 09/947,757, filed Sep. 6, 2001.72Office Action issued on Jul. 2, 2001 in connection with U.S. Appl. No. 09/493,527, filed Jan. 28, 2000.73Office Action issued on Jul. 9, 2004 in connection with U.S. Appl. No. 09/880,417, filed Jun. 13, 2001.74Office Action issued on Jun. 6, 2002 in connection with U.S. Appl. No. 09/493,527, filed Jan. 28, 2000.75Office Action issued on Mar. 23, 2001 in connection with U.S. Appl. No. 09/493,527, filed Jan. 28, 2000.76Office Action issued on Mar. 26, 2003 in connection with U.S. Appl. No. 09/947,757, filed Sep. 6, 2001.77Office Action issued on May 1, 2008 in connection with U.S. Appl. No. 11/655,610, filed Jan. 18, 2007.78Office Action issued on Nov. 19, 2003 in connection with U.S. Appl. No. 09/947,757, filed Sep. 6, 2001.79Office Action issued on Nov. 26, 2004 in connection with U.S. Appl. No. 09/947,757, filed Sep. 6, 2001.80Office Action issued on Oct. 2, 2008 in connection with U.S. Appl. No. 11/655,610, filed Jan. 18, 2007.81Office Action issued on Oct. 28, 2008 in connection with U.S. Appl. No. 11/237,598, filed Sep. 27, 2005.82Office Action issued on Oct. 30, 2007 in connection with U.S. Appl. No. 11/136,231, filed May 24, 2005.83Office Action issued on Oct. 9, 2003 in connection with U.S. Appl. No. 09/880,417, filed Jun. 13, 2001.84Office Action issued on Sep. 9, 2004 in connection with U.S. Appl. No. 10/352,597, filed Jan. 28, 2003.85PCT Written Opinion for International Application No. PCT/IL2005/01035 with a mailing date of Dec. 3, 2007.86Pending claims filed June 20, 2008 in Elena Feinstein, et al., U.S. Appl. No. 12/008,578, filed Jan. 11, 2008.87Pending claims in Elena Feinstein, et al., U.S. Appl. No. 11/827,199, filed Jul. 10, 2007.88Pending claims in Elena Feinstein, et al., U.S. Appl. No. 12/008,578, filed Jan. 11, 2008.89Pending claims in U.S. Appl. No. 11/827,199 as of Jan. 25, 2010 (US 2009/0082291).90Pending claims in U.S. Appl. No. 12/006,722 (US 2009/0105173), 2009.91Prakash TP et al. (2005) Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J. Med. Chem. 48(13):4247-53.92Result of consultation issued by the European Patent Office on Oct. 25, 2005 in connection with European Patent Application No. 00914455.1.93Scherer and Rossi (2004) Therapeutic Applications of RNA Interferences: Recent Advances in siRNA Design. Advances in Genetics 22:1-21.94Scherer and Rossi. (2003) "Approaches for the sequence—specific knockdown of mRNA". Nat. Biotechnol., 21(12): 1457-1465.95Search Report issued by the Australian Patent Office on May 14, 2008 in connection with Singaporean Application/Patent No. 0702035-7.96Second Written Opinion issued by the Australian Patent Office on May 26, 2009 in connection with Singapore Application No. 200702035-7.97Sioud, M. and Leirdal, M., (2004) Potential design rules and enzymatic synthesis of siRNAs. Methods Mol. Biol. 252:457-469.98Steele, R.J.C., et al., (1998) The p53 tumour suppressor gene. Br. J. Surg. 85:1460-1467.99Supavekin, S., et al., (2003) Differential gene expression following early renal ischemia/reperfusion. Kidney Int. 63:1714-1724.100TeKippe, M., et al.,(2003) Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice. Exp. Hematol. 31:521-527.101Tolentino, M.J., et al., (2004) Intravitreal Injection of Vascular Endothelial Growth Factor Small Interfering . . . , Retina 24:132-138.102Ui-Tei, K., et al., (2004) Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res. 32(3):936-948.103Wang, J. et al., (2003). "A Peptide Inhibitor of c-Jun N-Terminal Kinase Protects against Both Aminoglycoside . . . ," The J. of Neuroscience, 23(24):8596-8607.104Wlodarski, P., et al., (1998) Role of p53 in Hematopoietic Recovery After Cytotoxic Treatment. Blood 91(8):2998-3006.105Written Opinion issued by the Australian Patent Office on May 14, 2008 in connection with Singaporean Application/Patent No. 0702035-7.106Written Opinion of the International Searching Authority (ISA/US) issued on Dec. 3, 2007 in connection with International Application No. PCT/IL05/01035.107Zhang, M. et al., (2003). "Pifithrin-alpha Supresses p53 and Protects Cochlear and Vestibular Hair Cells From Cisplatin-Induced Apoptosis," Neuroscience, 120:191-205.108Zhang, M. et al., (2003). "Pifithrin-α Supresses p53 and Protects Cochlear and Vestibular Hair Cells From Cisplatin-Induced Apoptosis," Neuroscience, 120:191-205.* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS8637482Jun 7, 2010Jan 28, 2014Quark Pharmaceuticals, Inc.Methods for treating chronic kidney diseaseUS8642571Aug 31, 2012Feb 4, 2014Quark Pharmaceuticals, Inc.Therapeutic uses of inhibitors of RTP801US8785408Jun 26, 2008Jul 22, 2014Quark Pharmaceuticals, Inc.Compositions and methods for reducing or protecting against delayed graft function (DGF)US20100222409 *Jun 26, 2008Sep 2, 2010Hagar KalinskiCompositions and methods for inhibiting expression of pro-apoptotic genesWO2014043292A1Sep 12, 2013Mar 20, 2014Quark Pharmaceuticals, Inc.Double-stranded oligonucleotide molecules to p53 and methods of use thereofWO2015183842A1May 27, 2015Dec 3, 2015Quark Pharmaceuticals, Inc.Methods and compositions for preventing ischemia reperfusion injury in organs* Cited by examinerClassifications U.S. Classification514/44.00RInternational ClassificationA61K31/70Cooperative ClassificationC12N2320/30, C12N15/113, C12N15/1135, C12N2310/14, C07H21/02European ClassificationC07H21/02, C12N15/113BLegal EventsDateCodeEventDescriptionSep 28, 2015FPAYFee paymentYear of fee payment: 4RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services